Patents Assigned to Receptagen Corporation
  • Anti-receptor and growth blocking agents to the vitamin B12/transcobalamin II receptor and binding sites
    Publication number: 20030064066
    Abstract: There is disclosed anti-receptor and growth blocking agents to the vitamin B12/transcobalamin II receptor and binding sites. The anti-receptor and growth blocking agents antagonize or modulate the vitamin B12/transcobalamin II receptor or binding sites, causing cellular depletion of vitamin B12, thus inhibiting cell division or causing apoptosis. Anti-receptor and growth blocking agents of the present invention include proteins (such as antibodies and antibody derivatives), peptides and small organic molecules. In a preferred embodiment, the anti-receptor agent is an antibody to the vitamin B12/transcobalamin II receptor.
    Type: Application
    Filed: June 18, 2002
    Publication date: April 3, 2003
    Applicant: Receptagen Corporation
    Inventor: Alton Charles Morgan
  • Water soluble vitamin B.sub.12 receptor modulating agents and methods related thereto
    Patent number: 6083926
    Abstract: Vitamin B.sub.12 receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B.sub.12 receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety linked by a water-solublizing linker.
    Type: Grant
    Filed: November 23, 1998
    Date of Patent: July 4, 2000
    Assignees: The University of Washington, Receptagen Corporation
    Inventors: A. Charles Morgan, Jr., D. Scott Wilbur, Pradip M. Pathare
  • Methods of receptor modulation and uses therefor
    Patent number: 5869465
    Abstract: Receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are utilized for the treatment and diagnosis of a variety of disorders in warm-blooded animals, including neoplastic disorders. The receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: February 9, 1999
    Assignees: Receptagen Corporation, University of Washington
    Inventors: A. Charles Morgan, Jr., D. Scott Wilbur
  • Water soluble vitamin B.sub.12 receptor modulating agents and methods related thereto
    Patent number: 5840712
    Abstract: Vitamin B.sub.12 receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B.sub.12 receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety linked by a water-solublizing linker.
    Type: Grant
    Filed: October 19, 1995
    Date of Patent: November 24, 1998
    Assignees: Receptagen Corporation, University of WA
    Inventors: A. Charles Morgan, Jr., D. Scott Wilbur, Pradip M. Pathare
  • Receptor modulating agents
    Patent number: 5840880
    Abstract: Receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway. The receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: November 24, 1998
    Assignees: Receptagen Corporation, University of Washington
    Inventors: A. Charles Morgan, Jr., D. Scott Wilbur
  • Anti-receptor and growth blocking antibodies to the vitamin B.sub.12 /transcobalamin II receptor and binding sites
    Patent number: 5688504
    Abstract: There is disclosed anti-receptor and growth blocking agents to the vitamin B.sub.12 /transcobalamin II receptor and binding sites. The anti-receptor and growth blocking agents antagonize or modulate the vitamin B.sub.12 /transcobalamin II receptor or binding sites, causing cellular depletion of vitamin B.sub.12, thus preventing or inhibiting cell division or causing apoptosis. Anti-receptor and growth blocking agents of the present invention include proteins (such as antibodies and antibody derivatives), peptides and small organic molecules. In a preferred embodiment, the anti-receptor agent is an antibody to the vitamin B.sub.12 /transcobalamin II receptor.
    Type: Grant
    Filed: September 13, 1994
    Date of Patent: November 18, 1997
    Assignee: Receptagen Corporation
    Inventor: Alton Charles Morgan, Jr.